OptimizeRx (OPRX) Aktienübersicht
Die OptimizeRx Corporation ist ein Unternehmen für digitale Gesundheitstechnologie. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 3/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
Bei unseren Risikoprüfungen wurden keine Risiken für OPRX festgestellt.
OPRX Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
OptimizeRx Corporation Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$6.15 |
| 52-Wochen-Hoch | US$22.25 |
| 52-Wochen-Tief | US$4.54 |
| Beta | 1.08 |
| 1 Monat Veränderung | 21.78% |
| 3 Monate Veränderung | -0.16% |
| 1 Jahr Veränderung | -54.58% |
| 3 Jahre Veränderung | -58.56% |
| 5 Jahre Veränderung | -88.19% |
| Veränderung seit IPO | -97.59% |
Aktuelle Nachrichten und Updates
OPRX: Workflow Data And AI Tools Will Support Long Term Earnings Power
Analysts have reduced their price target on OptimizeRx from $17.00 to $9.00. They highlight lower revenue growth expectations, alongside resilient profit margin assumptions and a lower future P/E outlook.
OPRX: Profit Execution And Programmatic Ramp Will Support Future Upside
Analysts have trimmed the fair value estimate for OptimizeRx to $11.50 from $14.50. This reflects lower revenue growth expectations while acknowledging maintained profit margin forecasts and a still supportable forward P/E framework.Recent updates
OPRX: Workflow Data And AI Tools Will Support Long Term Earnings Power
Analysts have reduced their price target on OptimizeRx from $17.00 to $9.00. They highlight lower revenue growth expectations, alongside resilient profit margin assumptions and a lower future P/E outlook.OPRX: Profit Execution And Programmatic Ramp Will Support Future Upside
Analysts have trimmed the fair value estimate for OptimizeRx to $11.50 from $14.50. This reflects lower revenue growth expectations while acknowledging maintained profit margin forecasts and a still supportable forward P/E framework.
OPRX: Profit Stability And Buybacks Will Support Programmatic Recovery Potential
Analysts have trimmed their average price targets on OptimizeRx to a range of $7 to $20, citing recent revenue guidance cuts tied to pharma client disruptions and policy driven contract pressures. They still point to profit stability and potential longer term growth drivers such as DAAP subscriptions and programmatic channels as support for the stock's outlook.OPRX: Share Repurchases And Profit Focus Will Support Future Upside Potential
The analyst fair value estimate for OptimizeRx has been reduced from $20.00 to $18.00 per share, as analysts factor in recent price target cuts tied to softer revenue guidance, client disruption, and pressure on contract durations. These factors are partly balanced by stable profit forecasts and ongoing subscription momentum.Need To Know: Analysts Just Made A Substantial Cut To Their OptimizeRx Corporation (NASDAQ:OPRX) Estimates
The analysts covering OptimizeRx Corporation ( NASDAQ:OPRX ) delivered a dose of negativity to shareholders today, by...OPRX: Share Repurchases And Margin Gains Will Support Future Upside Potential
The analyst price target for OptimizeRx has moved from $32 to $20 as analysts factor in softer 2026 revenue expectations, lower revenue growth assumptions, falling peer multiples, and a higher discount rate, partly offset by improved profit margin forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Recent research updates show that while price targets on OptimizeRx have been reset lower, several bullish analysts still highlight positive angles around execution, profitability, and capital allocation.OPRX: Profit Execution And US$10m Buybacks Will Support Future Upside
Analysts have trimmed the blended price target for OptimizeRx to $14.50, reflecting softer 2026 revenue expectations, reduced revenue visibility, and lower peer multiples, partially offset by improved profit forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Street research on OptimizeRx has turned more cautious on the revenue outlook through 2026, but there is still a split between what bullish analysts focus on and what more bearish analysts are worried about.OPRX: Profit Focus And Buybacks Will Support Future Share Upside
Analysts have lowered their average price targets for OptimizeRx into the low to mid teens in dollar terms, citing reduced 2026 revenue visibility, softer pharma marketing budgets, pressure from peer multiples, and a greater focus on profitability and share repurchases. Analyst Commentary Street research on OptimizeRx has converged around lower price targets but with different degrees of optimism on execution, growth prospects, and valuation.OPRX: Margin Discipline And Buybacks Will Support Future Upside Potential
Analysts have reduced the fair value estimate for OptimizeRx from $24.33 to $14.50, citing lower revenue growth expectations, reduced revenue visibility into 2026, and lower peer P/E multiples. These factors are partly offset by firmer profit margin forecasts and buy ratings that remain in place across several firms.OPRX: Expanded Point Of Care Network Will Support Further Upside
Analysts have fine tuned their OptimizeRx price target to $24.33. This reflects updated assumptions around the discount rate, long term revenue growth, profit margin and future P/E multiple.OPRX: New Data Partnerships Will Support Long Term Earnings Power
Analysts now maintain their price target for OptimizeRx at $17.00, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E that they view as broadly offsetting each other. What's in the News Announced a data collaboration with Experian at CES 2026 to connect OptimizeRx Micro-Neighborhood audiences with Experian's identity graph for onboarding, curation, and measurement of consumer audiences at scale (Client Announcements).OPRX: Q3 Outperformance And 2026 Guidance Will Strengthen Long Term Earnings Power
Analysts have lifted their average price targets on OptimizeRx into a US$21 to US$32 range, citing stronger than guided Q3 performance, improved visibility after 2024, and expectations for ongoing double digit growth with expanding margins. Analyst Commentary Street research after the Q3 report has centered on stronger than guided results and higher price targets, with analysts highlighting improved earnings and better visibility beyond 2024.OPRX: Q3 Execution Rebound And 2026 Guidance Will Support Further Upside
Analysts have lifted their blended price targets on OptimizeRx to a range of US$21 to US$32, citing stronger than guided Q3 revenue and EPS, improved visibility after 2024 execution issues, and continuing momentum that supports expectations for double digit growth with expanding margins. Analyst Commentary Across the Street, bullish analysts are taking Q3 as a sign that OptimizeRx may be getting back on track after earlier execution issues, and they have shifted their valuation ranges higher as a result.OPRX: Higher Guidance And Margin Expansion Will Reshape Long Term Earnings Power
Analysts have lifted their fair value estimate for OptimizeRx from US$11.00 to US$17.00, reflecting higher price targets supported by recent revenue and EPS outperformance, improved growth visibility, and expectations for margin expansion. Analyst Commentary Street research on OptimizeRx has been broadly positive around the latest quarter, with several firms raising their price targets after revenue and EPS outperformance and clearer guidance.OPRX Will Extend Double Digit Revenue Trajectory With New Multi Year Partnerships
Analysts have lifted their price target on OptimizeRx by $5 to $32 per share, citing consistently strong quarterly outperformance, improving visibility after last year's weak execution, and a more durable outlook for double digit revenue growth and expanding margins. Analyst Commentary Bullish analysts are increasingly aligned around a constructive view of OptimizeRx, pointing to a series of price target hikes following its latest quarterly results.OPRX: Recurring Revenue Shift And 2026 Guidance Will Drive Future Upside
Analysts have nudged their price targets on OptimizeRx higher, with recent increases across the Street ranging from about $1 to $10 per share to reflect stronger than expected Q3 revenue and EPS, improved visibility, and confidence in sustained double digit growth and margin expansion. Analyst Commentary Bullish analysts highlighted that the latest quarter materially exceeded revenue expectations, driving meaningful EPS upside and reinforcing confidence in a durable, double digit growth profile.OPRX: Multi-Year Guidance and Recurring Revenue Will Drive Upside Momentum
OptimizeRx's analyst price target has increased from $22 to approximately $24.33 per share. This reflects ongoing revenue outperformance and improved visibility that analysts attribute to strong quarterly results and the company's growing momentum.OptimizeRx Corporation's (NASDAQ:OPRX) 33% Share Price Plunge Could Signal Some Risk
OptimizeRx Corporation ( NASDAQ:OPRX ) shareholders won't be pleased to see that the share price has had a very rough...OPRX: Expanding Margins and Subscription Model Will Drive Shareholder Value Forward
OptimizeRx's analyst fair value target has been raised from $19 to $22.00 per share. This change reflects stronger quarterly results, improved growth prospects, and expanding profit margins, according to analysts.Is OptimizeRx (NASDAQ:OPRX) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Are Investors Undervaluing OptimizeRx Corporation (NASDAQ:OPRX) By 39%?
Key Insights OptimizeRx's estimated fair value is US$28.97 based on 2 Stage Free Cash Flow to Equity OptimizeRx's...Pharmaceutical Digital Engagement Will Unlock Future Value
Despite near-term cautious revenue guidance, analysts remain optimistic on OptimizeRx due to Q2 earnings outperformance, improved management transparency, and ongoing strategic initiatives, maintaining the consensus price target at $19.00. Analyst Commentary Bullish analysts highlight OptimizeRx’s Q2 revenues and adjusted EBITDA significantly surpassing forecasts.Even With A 33% Surge, Cautious Investors Are Not Rewarding OptimizeRx Corporation's (NASDAQ:OPRX) Performance Completely
OptimizeRx Corporation ( NASDAQ:OPRX ) shares have continued their recent momentum with a 33% gain in the last month...
A Subscription Model And EHR Network Will Reshape Healthcare
Transitioning to a subscription-based model aims to enhance revenue predictability and improve net margins with recurring income.Is OptimizeRx Corporation (NASDAQ:OPRX) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Using the 2 Stage Free Cash Flow to Equity, OptimizeRx fair value estimate is US$6.02 Current share price...We Think OptimizeRx (NASDAQ:OPRX) Has A Fair Chunk Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...At US$6.29, Is It Time To Put OptimizeRx Corporation (NASDAQ:OPRX) On Your Watch List?
OptimizeRx Corporation ( NASDAQ:OPRX ), is not the largest company out there, but it received a lot of attention from a...Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost
OptimizeRx Corporation ( NASDAQ:OPRX ) shareholders are no doubt pleased to see that the share price has bounced 30% in...Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Aktionärsrenditen
| OPRX | US Healthcare Services | US Markt | |
|---|---|---|---|
| 7D | 1.2% | 0.6% | -0.4% |
| 1Y | -54.6% | -38.7% | 18.4% |
Rendite im Vergleich zur Industrie: OPRX unter dem Niveau der Branche US Healthcare Services , die im vergangenen Jahr eine Rendite von -38.7% erzielte.
Rendite vs. Markt: OPRX hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 18.4 erzielte.
Preisvolatilität
| OPRX volatility | |
|---|---|
| OPRX Average Weekly Movement | 10.5% |
| Healthcare Services Industry Average Movement | 9.8% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: OPRX hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: OPRXDie wöchentliche Volatilität (10%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2006 | 133 | Steve Silvestro | www.optimizerx.com |
Die OptimizeRx Corporation ist ein Unternehmen für digitale Gesundheitstechnologie. Das Unternehmen bietet die Dynamic Audience Activation Platform an, die dynamische Zielgruppen mit prädiktiven Analysen durch maschinelle Lernmethoden generiert; Micro-Neighborhood Targeting, das Verbraucherzielgruppen mit einem datenschutzfreundlichen Prozess erstellt; Profiler, der Einblicke in die Zielkunden seiner Kunden bietet; Banner-Botschaften, einschließlich Markenbotschaften, Botschaften zur therapeutischen Unterstützung, Botschaften zur Erschwinglichkeit, Informationen zu Arzneimitteln mit begrenztem Vertrieb und Botschaften zu Patientenunterstützungsprogrammen durch medizinisches Fachpersonal; und Lösungen für die Medienausführung, die Botschaften über ein Omnichannel-Netzwerk für Verbraucher bereitstellen, einschließlich programmatischer Anzeigen, programmatischem vernetztem Fernsehen/Over-the-Top, programmatischen sozialen Medien, adressierbarem Fernsehen, digitalem Out-of-Home, programmatischem Audio und E-Mail/Direktpost. Das Unternehmen bietet auch Apothekenwarnungen, die Apotheken anzeigen, die verschreibungspflichtige Medikamente vorrätig haben, und Lösungen für Finanznachrichten, die Verschreibern Sichtbarkeit von Marken-Zuzahlungsangeboten für Patienten direkt in elektronischen Krankenakten und ePrescribing-Plattformen bieten.
OptimizeRx Corporation's Grundlagenzusammenfassung
| OPRX grundlegende Statistiken | |
|---|---|
| Marktanteil | US$118.03m |
| Gewinn(TTM) | US$6.84m |
| Umsatz(TTM) | US$107.35m |
Ist OPRX zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| OPRX Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$107.35m |
| Kosten der Einnahmen | US$32.16m |
| Bruttogewinn | US$75.18m |
| Sonstige Ausgaben | US$68.35m |
| Gewinn | US$6.84m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 0.36 |
| Bruttomarge | 70.04% |
| Nettogewinnspanne | 6.37% |
| Schulden/Eigenkapital-Verhältnis | 18.0% |
Wie hat sich OPRX auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/08 10:43 |
| Aktienkurs zum Tagesende | 2026/07/08 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
OptimizeRx Corporation wird von 12 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Anderson Schock | B. Riley Securities, Inc. |
| Constantine Davides | Citizens JMP Securities, LLC |
| Eric Martinuzzi | Lake Street Capital Markets, LLC |